Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.72 |
| ▸ | AKR1B1 | P15121 | 10/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274589 | 0.93 | PTGDR2 (0.63) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1251040 | 0.86 | PTGDR2 (0.54) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1252380 | 0.85 | PTGDR2 (0.69) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1252422 | 0.85 | PTGDR2 (0.72) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1405977 | 0.84 | PTGDR2 (1.00) | PTGDR2AKR1B1CYP2C9 | |
| Ammonia Solution, Strong SCHEMBL27605865 | 0.83 | PTGDR2 (0.98) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1251019 | 0.83 | PTGDR2 (0.68) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1251026 | 0.83 | PTGDR2 (0.68) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1249482 | 0.82 | PTGDR2 (0.80) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL3563092 | 0.81 | PTGDR2 (0.69) | PTGDR2AKR1B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178764-A1 | Novel Compounds | BONNERT ROGER (GB) | 2012-07-12 | — | — | US | claimed |
| US-20110263614-A1 | Novel compounds | BONNERT ROGER | 2011-10-27 | — | — | US | claimed |
| US-20090163518-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | claimed |
| US-20080249110-A1 | Novel Substituted 3-Sulfur Indoles | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | US | claimed |
| EP-1656346-A1 | NOVEL SUBSTITUTED 3-SULFUR INDOLES | AstraZeneca AB (SE) | 2006-05-17 | — | — | EP | claimed |
| WO-2004106302-A1 | NOVEL SUBSTITUTED 3-SULFUR INDOLES | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2790696-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | Atopix Therapeutics Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088109-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | OXAGEN LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| US-20120178764-A1 | Novel Compounds | BONNERT ROGER (GB) | 2012-07-12 | — | — | US | disclosed |
| US-20110263614-A1 | Novel compounds | BONNERT ROGER | 2011-10-27 | — | — | US | disclosed |
| US-7687535-B2 | Substituted 3-sulfur indoles | ASTRAZENECA AB (SE) | 2010-03-30 | — | — | US | disclosed |
| US-20090163518-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| EP-2025670-A1 | 3-(Phenyl or quinolyl)thio-1H-indole-1-acetic acid derivatives as modulators of CRTh2 receptor activity | AstraZeneca AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20080249110-A1 | Novel Substituted 3-Sulfur Indoles | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178764-A1 | Novel Compounds | IDO1, IDO2, MTNR1A | PTGDR2 227/4885AKR1B1 1072/4885CYP2C9 967/4885 |
| US-20090163518-A1 | Novel Compounds | IDO1, IDO2, MTNR1A | PTGDR2 227/4885AKR1B1 1072/4885CYP2C9 967/4885 |
| US-20080249110-A1 | Novel Substituted 3-Sulfur Indoles | IDO1, IDO2, AANAT | PTGDR2 885/4885AKR1B1 2196/4885CYP2C9 1092/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | PTGDR2 59/4885AKR1B1 3801/4885CYP2C9 2737/4885 |
| US-20110263614-A1 | Novel compounds | IDO1, IDO2, MTNR1A | PTGDR2 227/4885AKR1B1 1072/4885CYP2C9 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.